Funotinitib maleate

Flonoltinib maleate (FM) is an investigational drug developed by Zenitar (赜灵生物), a Qiming Venture Partners portfolio company — described in funding announcements as a highly selective, potential first-in-class triple inhibitor of JAK2/FLT3/CDK6, with pivotal trials underway following Zenitar's nearly RMB 400 million Series B+ round in August 2025 . Its lead indication is myelofibrosis: per Qiming's portfolio update, at the 2025 ASH annual meeting FM reported positive topline Phase IIb results, beating the standard-of-care drug ruxolitinib — both dose arms hit the primary endpoint (SVR35 at week 24) and the high-dose arm showed nearly double the symptom improvement (TSS50) of the active comparator . By January 2026 it had been admitted into China's CDE Breakthrough Therapy program for Ph-negative myeloproliferative neoplasms (MF, PV, ET), adding to earlier US orphan drug recognition; Zenitar's next step, in founder and CEO Chen Lijuan's words, is a pivotal Phase III trial in China alongside US and European registration planning .